Please ensure Javascript is enabled for purposes of website accessibility

Here's What to Expect from Vaccine Makers in the Long Term

By Adria Cimino - Updated Jun 23, 2021 at 7:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The revenue opportunity should be clear.

Experts say the coronavirus will be around well into the future. And that means so will the need for vaccines. In this Motley Fool Live video recorded on May 28, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss what we may expect from coronavirus vaccine makers in three to five years.

Olivia Zitkus: With all that in mind, what do you think the landscape of vaccines might look like in three years or in five years? Do you think we're still going to have a lot of options to choose from? I guess we don't even know if we will need all those options. We still have yet to figure that out and for experts to tell us. But what do you think about the outlook for few years or five years?

Adria Cimino: I think there'll be a few market leaders not just one, because clearly one company couldn't serve all of the countries. So there's going to have to be a few out there. We'll also know more about annual revenue. We'll know is this going to be something that is going to keep growing? Is it going to stabilize and plateau and then just stay at a certain level? We'll have -- and this is like three years out. We should have ideas about these things. Some of the players might drop out. Some of the farther behind players might decide, wait a minute, let's just move on to other things because our candidate just isn't working. So there might be fewer players in the end. Farther down the road, talking five years out, I'd say there'll be a lot of innovation. Just looking at the flu vaccine. There's already flu vaccines out there. But like Novavax (NVAX -5.56%) has a flu vaccine candidate that is close to market. It met all primary endpoints in the clinical trial. So that didn't stop them from developing a flu vaccine. There are a lot of companies that could be developing better vaccines well into the future. One thing that we definitely look for is a combined flu and COVID vaccine. That's something that Novavax is working on, Moderna (MRNA -5.06%) is also working on and that's something that will probably be about five years out. We can imagine that coming out.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus owns shares of Moderna Inc. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$37.18 (-5.56%) $-2.19
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$150.00 (-5.06%) $-8.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.